http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112662621-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf415258683635c3e869f8fdd14bb250 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 |
| filingDate | 2020-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd0a98d0215012879d7bedbbcd06dc9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_822761292b89a7c8d8d50e2a2ce8fe46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fa5de8fa936bad63a4e9b67c2956810 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d0e9c6e102b7419c1ef2889899b6d29 |
| publicationDate | 2021-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112662621-A |
| titleOfInvention | A method and application for reversing the aging of mesenchymal stem cells |
| abstract | The present invention provides a method and application for reversing the aging of mesenchymal stem cells, wherein the method includes: providing aged mesenchymal stem cells; providing a working solution comprising TGF-βRI kinase inhibitor II and valproic acid; using The working solution processes the aged mesenchymal stem cells to obtain rejuvenated mesenchymal stem cells. The invention combines TGF-βRI kinase inhibitor II and valproic acid to activate the stemness-related genes of senescent mesenchymal stem cells and enhance the multi-directional differentiation potential, thereby effectively delaying or reversing the senescence process of MSCs in the in vitro culture system, Maintaining the original biological characteristics of MSCs will help to further develop and improve the preparation process of MSCs and improve the clinical therapeutic effects of MSCs. |
| priorityDate | 2020-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 170.